A Clinical Study of GK02 in Malignant Ascites

Summary

A single-arm, single-center, open-label clinical study comprising three cohorts, evaluating the safety, preliminary efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) characteristics of autologous tumor-reactive T cells (GK02) derived from malignant ascites caused by advanced solid tumors. The trial initially plans to enroll 9 subjects with malignant ascites caused by advanced solid tumors.

Timeline

Start

2025-09-16

Primary completion

2026-12-17

Completion

2027-12-17

Drugs

Indications